UK's health regulator on Monday approved GSK's twice-yearly drug for use as an add-on treatment for asthma in patients aged ...

Milestone Pharmaceuticals won FDA approval for a new nasal-spray medicine to treat episodes of paroxysmal supraventricular ...

GlaxoSmithKline ( ($GB:GSK) ) just unveiled an update. GSK has announced the purchase of 230,000 of its own ordinary shares as part of its ongoing ...

The Magnum Ice Cream Company, the recent ice cream spin-off from Unilever, rose to the top of the pan-European benchmark, ...

Phase 3 studies point to sustained disease control in patients who remain symptomatic despite standard therapies.

The boss of Britain’s largest drug developer has praised the US as the best place to invest amid fears over the waning appeal ...

Investing.com -- GSK plc (LSE:GSK) announced Friday that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended expanding the indication of its RSV ...

The Non-Opioid Therapeutics Market is rapidly expanding due to increased demand for safer pain management Non-Opioid Therapeutics Market Non-Opioid Therapeutics Market Dublin, Dec. 11, 2025 (GLOBE ...

DelveInsight’s “Post Traumatic Stress Disorder Market Insights, Epidemiology, and Market Forecast-2034″ report offers an ...

Detailed price information for Ideaya Biosciences Inc (IDYA-Q) from The Globe and Mail including charting and trades.

Harvey Jones has been hunting for the best shares to buy for his SIPP, and found what he thinks is one in a surprising place.

(Alliance News) - Outgoing GSK PLC Chief Executive Officer Emma Walmsley has said the US is the best place to invest, in the latest blow to Britain's pharmaceutical sector, after a raft of drugs firms ...